Dr Reddys Laboratories has allotted 13,080 equity shares under ESOS on 19 December 2024. Powered by Capital Market - Live News

Dr Reddys Laboratories announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In 2023, Dr. Reddy`s entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab. Under this agreement, Dr. Reddy`s obtained exclusive rights to develop and commercialise Toripalimab in 21 countries including India, South Africa, Brazil and various countries in Latin America. Additionally, the agreement allows Dr. Reddy`s to expand the scope of the license to cover Australia, New Zealand and nine other countries.With this launch by Dr. Reddy`s, India becomes the third country in the world after China and the United States to receive access to this next generation PD-1 inhibitor. Dr. Reddy`s will market it under the brand name Zytorvi� in India.The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Toripalimab is indicated as first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with gemcitabine and cisplatin. This combination has shown a 48% reduction in risk of progression or death. Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.Powered by Capital Market - Live News

Dr Reddys Laboratories has received an order dated 12 November 2024, from COFEPRIS (Comisi�n Federal para la Protecci�n Contra Riesgos Sanitarios) health department of Mexico. The drug regulatory body of Mexico (Comisi�n Federal para la Protecci�n contra Riesgos Sanitarios) has imposed a penalty of MXN 651, 420 (~Rs 27 Lakh) on the Company for deviation from prescribed guidelinesin filing intimation of import of a reference standard for one of the company`s APIs. Additionally, the fine was imposed due to an error in the date of the invoice and also name of the reference standard Vs import license. Powered by Capital Market - Live News

Net profit of Dr Reddy`s Laboratories declined 15.28% to Rs 1255.70 crore in the quarter ended September 2024 as against Rs 1482.20 crore during the previous quarter ended September 2023. Sales rose 16.51% to Rs 8016.10 crore in the quarter ended September 2024 as against Rs 6880.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales8016.106880.20 17 OPM %25.9029.19 - PBDT2314.402292.20 1 PBT1917.401916.70 0 NP1255.701482.20 -15 Powered by Capital Market - Live News

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy`s Laboratories has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study - India`s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients.After reviewing the Phase 1 data, the Indian Regulatory Agency i.e., Drugs Controller General of India (DCGI), has given the nod to commence Phase 2 part of the trial. These results of Phase 1 were presented at the 21st annual meeting of the International Myeloma Society at Rio De Janeiro, Brazil, held recently.Ribrecabtagene autoleucel is an autologous anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen binding domain and lentivirus as a vector. DRL-1801 for the clinical trials is manufactured at the CAR-T GMP manufacturing facility at Aurigene Oncology, Bangalore. Powered by Capital Market - Live News